Condition
IgE-Mediated Hypersensitivity
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 1 (1)
P 4 (1)
Trial Status
Unknown1
Recruiting1
Not Yet Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07408869Phase 1Not Yet RecruitingPrimary
A Phase 1 Study of Cizutamig in IgE Mediated Diseases
NCT07316465Not ApplicableRecruiting
Birth Cohort: Development of IgE Autoantibodies in Newborns With (High Risk of) Atopic Dermatitis
NCT01159379Phase 4UnknownPrimary
Safety of Ertapenem in Beta-lactam Allergic Patients.
Showing all 3 trials